Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Jun;7(3):146-51.
doi: 10.1177/1756287215576626.

Tadalafil therapy for erectile dysfunction following prostatectomy

Ateş Kadıoğlu  1 , Mazhar Ortaç  1 , Murat Dinçer  1 , Gerald Brock  2
Affiliations
Review

Tadalafil therapy for erectile dysfunction following prostatectomy

Ateş Kadıoğlu et al. Ther Adv Urol. 2015 Jun.

Abstract

Erectile dysfunction is a major complication affecting the quality of life of patients and partners after radical prostatectomy. Evolving evidence suggests that early penile rehabilitation may provide better erectile function after surgery. Phosphodiesterase type 5 (PDE-5) inhibitors are routinely considered a first-line treatment option in most algorithms for penile rehabilitation owing to their efficacy, ease of use, wide availability and minimal morbidity. Tadalafil is a long-acting, potent PDE-5 inhibitor for erectile dysfunction, with demonstrated effect in animal studies at preserving penile smooth muscle content and prevention of fibrosis of cavernosal tissue. This article evaluates the existing literature on tadalafil and critically analyzes its impact on erectile function following radical prostatectomy.

Keywords: erectile dysfunction; penile rehabilitation; radical prostatectomy; tadalafil.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest statement: We certify that there is no conflict of interest with any financial organization regarding the material discussed in the manuscript. Dr Brock is on the speakers’ bureau and advisory board for Lilly and owns stock in, and is on the speakers’ bureau and advisory board for Pfizer.

Similar articles

See all similar articles

Cited by

References

    1. Alemozaffar M., Regan M., Cooperberg M., Wei J., Michalski J., Sandler H., et al. (2011) Prediction of erectile function following treatment for prostate cancer. JAMA 306: 1205–1214. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3831607&tool=p... (accessed 26 February 2015). - PMC - PubMed
    1. Carrier S., Zvara P., Nunes L., Kour N., Rehman J., Lue T. (1995) Regeneration of nitric oxide synthase-containing nerves after cavernous nerve neurotomy in the rat. J Urol 153: 1722–1727. - PubMed
    1. Champion H., Abdel-Mageed A., Hellstrom W. (2003) Cavernous neurotomy causes hypoxia and fibrosis in rat corpus cavernosum. J Androl 24: 239–245. - PubMed
    1. Coelho R., Rocco B., Patel M., Orvieto M., Chauhan S., Ficarra V., et al. (2010) Retropubic, laparoscopic, and robot-assisted radical prostatectomy: a critical review of outcomes reported by high-volume centers. J Endourol 24: 2003–2015. - PMC - PubMed
    1. Ficarra V., Novara G., Ahlering T., Costello A., Eastham J., Graefen M., et al. (2012) Systematic review and meta-analysis of studies reporting potency rates after robot-assisted radical prostatectomy. Eur Urol 62: 418–430. - PubMed

LinkOut - more resources